Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
B-Lymphocytes
/ drug effects
Biomarkers
/ blood
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
Chile
Female
Granzymes
/ metabolism
Healthy Volunteers
Humans
Immunity, Cellular
/ drug effects
Immunity, Humoral
/ drug effects
Immunization Schedule
Immunogenicity, Vaccine
Immunologic Memory
/ drug effects
Interferon-gamma
/ metabolism
Male
Middle Aged
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Time Factors
Treatment Outcome
COVID-19
CoronaVac
SARS-CoV-2
herd immunity
immunological memory
neutralizing antibodies
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
08
2021
accepted:
14
12
2021
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
Identifiants
pubmed: 35173705
doi: 10.3389/fimmu.2021.766278
pmc: PMC8841433
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Biomarkers
0
COVID-19 Vaccines
0
IFNG protein, human
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Interferon-gamma
82115-62-6
GZMB protein, human
EC 3.4.21.-
Granzymes
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
766278Informations de copyright
Copyright © 2022 Escobar, Reyes-López, Acevedo, Alonso-Palomares, Valiente-Echeverría, Soto-Rifo, Portillo, Gatica, Flores, Nova-Lamperti, Barrera-Avalos, Bono, Vargas, Simon, Leiva-Salcedo, Vial, Hormazabal, Cortes, Valdés, Sandino, Imarai and Acuña-Castillo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Virus Res. 2009 Jun;142(1-2):19-27
pubmed: 19185596
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Sci Rep. 2018 Feb 15;8(1):3087
pubmed: 29449630
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Ann Palliat Med. 2021 Apr;10(4):3706-3714
pubmed: 33615814
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Sci Adv. 2021 Feb 12;7(7):
pubmed: 33579701
Trials. 2020 Oct 15;21(1):853
pubmed: 33059771
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097